C11797: Blood Test Biomarkers for Pulmonary Arterial Hypertension
Novelty:
This invention is a novel set of circulating biomarkers found in serum and plasma which can be used for diagnostic and prognostic testing of Pulmonary Arterial Hypertension (PAH).
Value Proposition:
Currently, the first line of treatment for PAH is prescribing vasodilators, which are not effective in up to 30% of patients causing poor prognosis and eventual lung transplant. This technology employs specific prognostic and diagnostic markers that are capable of identifying whether or not the patient either has the condition or is responding appropriately to the treatment. Other advantages include:
• Simple and effective blood test can be developed to improve clinical assessment of patients, especially children.
• Potential development of diagnostic test to stratify patient’s extent of PAH, leading to additional treatment options.
• Early diagnoses with simple test can speed patient to therapy, reducing the need for more aggressive options.
Technical Details:
Johns Hopkins University researchers have identified multiple biomarkers of pulmonary hypertension found in serum and plasma. They utilized a proteomics approach to determine the correct protein targets for assay. This discovery could lead to the development and validation of specific diagnostic/prognostic biomarker panels for PAH.
Looking for Partners:
To develop and commercialize the technology as a prognostic/diagnostic test for Pulmonary Arterial Hypertention.
Stage of Development:
Discovery
Data Availability:
Under CDA/NDA
Publications/Associated Cases: US 20150072360
